Special Issue

The Global Need for New Antimicrobial and Antibiofilm Agents

Message from the Guest Editors

New antimicrobials that are able to hit resistant pathogens and biofilm are strongly needed. It is time for action in order to address antibiotic-resistant strains, especially carbapenem-resistant Enterobacteriaceae (CRE), *Acinetobacter baumannii* (CRAB) and *Pseudomonas aeruginosa* (CRPA), which are resistant to last-resort antibiotics. This Special Issue is aimed at researchers who focus their scientific interest on drug discovery strategies to develop new molecules with antimicrobial action and antibiofilm. Potential topics may include but are not limited to antimicrobial peptides of various organisms, natural substances, nanoparticles of microbial origin, and small synthetic organic molecules. Topics such as strategies aimed at improving the efficiency of conventional antibiotics through nano/micro-release and micro-release systems with functionalized polymers are also welcome. **Keywords:** antimicrobial agents; antibiofilm agents; anti-virulence agents; antimicrobial peptides; natural substance; synthetic small organic molecules; improvement of conventional antibiotics

Guest Editors

Dr. Domenico Schillaci

Dr. Valentina Catania

Dr. Maria Vitale

Deadline for manuscript submissions

closed (28 February 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/82160

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI